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Randomised trial of chemotherapy versus endocrine therapy in patients
presenting with locally advanced breast cancer (a pilot study)
J.-C. Gazet, H.T. Ford & R.C. Coombes
Combined Breast Clinic, St. George's Hospital, Blackshaw Road, London SWJ7OQT, UK.
Summary Sixty patients with locally advanced breast cancer, but with no evidence of distant metastases were
randomised to receive primary endocrine therapy or chemotherapy after assessment and 'Trucut' biopsy of the
primary tumour. After 12 weeks all patients were assessed. Eight out of 30 (27%) of the patients who received
chemotherapy showed complete clinical regression of the primary cancer, eight patients' tumours had regressed
by more than 50%, and ten showed a 25-50% reduction in bi-dimensional diameter. Only four (13%)
patients' tumours failed to reduce in size. Seven patients were judged to require mastectomy at the end of the
12 week period of treatment with chemotherapy. In contrast, only three out of 30 (10%) patients receiving
endocrine therapy showed a greater than 50% reduction in tumour size, and four patients had a 25-50%
reduction at 12 weeks. The remaining patients' tumours either stabilised (12 patients) or enlarged (II patients).
We conclude that primary chemotherapy in patients with primary breast cancer is more effective in rapidly
reducing the size of the primary breast cancer than endocrine therapy (P = 0.001) and alters significantly the
future management of these patients. However, at 65 weeks on completion of the follow-up, there is no
significant difference in the number of patients' disease-free, locally or distant recurrent, or dead.
It is now generally agreed that conservative surgery by
tumour excision is adequate for small cancers (TI and T2)
but the management of patients with locally advanced car-
cinoma of the breast (T3, T4, NO-2 MO) presents a
therapeutic challenge. Local radiation is only partially suc-
cessful in controlling local tumour growth, with a local
relapse rate in 36-72% of patients (Chu et al., 1984; Bruck-
man et al., 1979; Rubens et al., 1977). Similarly conservative
surgery has a similar local relapse rate (Fisher et al., 1985).
However, combination therapy of surgery and radiotherapy
will control local disease (Veronesi et al., 1986). The problem
in the use of these modalities is the high rate of distant
metastases uninfluenced by the control of the local disease in
the short term.
Primary systemic treatment either with chemotherapy
(Delena et al., 1981; Swain et al., 1987; Perloff et al., 1988) or
endocrine therapy has been used in the past (Forrest et al.,
1986; Gazet et al., 1988). However, no randomised trial has
been carried out to examine the relative merits of these two
forms of systemic treatment when used in primary treatment
of breast cancer in the short term, to influence the secondary
treatment offered (surgery or radiotherapy) or in the long
term, in the control and reduction of the incidence of meta-
static disease.
The objective of this pilot study was 2-fold. First to com-
pare the effectiveness of these two forms of treatment in the
short term (12 weeks) and assess the impact of therapy on
subsequent treatment and secondly to review the long term
effect of therapy at 1 year post primary management (65
weeks).
Patients and treatment details
Between December 1986 and January 1989, 60 patients, aged
34-69 who presented at the Combined Breast Clinic with
locally advanced breast cancer (T3, T4, NO-N2, MO, - UICC
TNM Classification (Beahrs & Myers, 1983), were ran-
domised to receive primary treatment with chemotherapy or
endocrine therapy. Following preliminary screening by
mammography and fine needle aspiration cytology, they were
fully staged to exclude metastatic disease. This included full
clinical examination, limited skeletal survey, chest X-ray,
liver function tests, calcium and full blood count with bone
Correspondence: J.-C. Gazet.
Received 3 April 1990; and in revised form 9 August 1990.
scan and liver ultrasound. All patients had a 'Trucut' biopsy
of the breast carcinoma which confirmed the presence of an
infiltrating ductal carcinoma in 55 patients and infiltrating
lobular carcinoma in five patients.
The patients were fully informed of the object of the trial
and written consent obtained in every case according to the
Helsinki agreement. The patients were randomised to receive
primary treatment with chemotherapy or endocrine therapy
over 12 weeks. Patients randomised to receive endocrine
therapy were treated with 4-hydroxyandrostenedione 250 mg
every 2 weeks by intramuscular injection if postmenopausal
(Coombes et al., 1984; Stein et al., 1989), or if
premenopausal they received the luteinising hormone releas-
ing hormone analogue goserelin (Zoladex) 3.6 mg sub-
cutaneously every 4 weeks. Those randomised to receive
chemotherapy received mitozantrone 7 mg m-2, and
methotrexate 35 mg m-2, 3 weekly four times and mitomycin
C 7mgm2, 6 weekly, intravenously (Powles et al., 1987).
There was no significant difference in the comparative age;
menopausal status, TNM stage or histology in the two
groups (Table I).
All patients were assessed clinically at 4 weekly intervals.
Tumour size was measured using calipers and compared with
size at presentation. Response was defined by standard UICC
criteria (Hayward et al., 1977) i.e. complete response was
defined as no palpable mass, partial response as at least a
50% reduction in bidimensional diameter; stable disease
either less than a 50% reduction in size or no change.
Progressive disease was defined as a >25% increase in
bidimensional diameter. To be considered a response, all
measurements had to be confirmed as such in two subsequent
separate clinical examinations at 4 weeks apart. At 12 weeks
from the start of treatment, the patients were completed
restaged and regraded according to the TNM Classification.
The treatment policy adopted at this stage depended upon
the TNM Classification and the wishes ofthe patient. Thus if
the tumour was considered operable, patients with TI and T2
tumours were offered wide local excision; those with T3 and
T4 tumours, radical mastectomy. If the tumour was
inoperable, the patients were offered radical radiotherapy.
Where no tumour was clinically palpable, patients were
offered radiotherapy as an alternative to radical surgery.
Systemic treatment was only continued post-operatively if
the primary tumour either responded or stabilised on
systemic therapy: chemotherapy was continued for a further
four cycles and endocrine therapy for a further 65 weeks. All
patients were staged at the end of the first 12 weeks systemic
therapy and/or at the end of the period of treatment.
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Table I Details of patients at induction
Endocrine Chemotherapy
therapy No (%) No (%)
Mean age (yrs) 58.9 50.8
Range 42-69 34-69
Premenopausal patients 6 (20) 10 (30)
No with T3 carcinomas (%) 20 (67) 19 (63)
No with T4 carcinomas (%) 10 (33) 11 (37)
No with clinically involved 18 (60) 14 (47)
nodes
Histology: infiltrating ductal 29 (97) 26 (87)
carcinomas
Histology: infiltrating lobular 1 (3) 4 (13)
carcinomas
Results of treatment
Table II shows the results of therapy at 12 weeks as assessed
by UICC criteria of response and by change of T stage.
Chemotherapy resulted in a total of eight complete re-
sponders out of 30 patients at 3 months whereas no complete
responders were seen in patients receiving endocrine therapy
(P = <0.001). Eight patients achieved a partial response
following chemotherapy and three following endocrine
therapy, thus indicating a 53% response rate for
chemotherapy with a 10% response rate for endocrine
therapy (P = <0.001) (Fisher's exact test). A 'minimal' re-
sponse (between 25-50% reduction) was seen in a further
ten patients in the chemotherapy group compared with only
four patients in the endocrine therapy.
Using the standard TNM staging, nine out of 30 on endo-
crine therapy and 19 out of 30 having chemotherapy were
downstaged (Table II), (P = 0.001). These do not correspond
necessarily with the UICC criteria as TNM consider diameter
and the UICC percentage reduction in size, but certainly
confirm the changes seen.
Table III shows that the definitive treatment at 12 weeks
also differed between the two groups. Thus, surgery was
carried out in only seven patients in the chemotherapy group
whereas this was carried out in 16 patients on the endocrine
therapy arm.
We examined side effects in both arms of the study. In the
endocrine arm, only 5/30 patients had side effects (4-
hydroxyandrostenedione: pain at injection site (n = 2);
anaphylactoid reaction (n = 1); depression (n = 1). Goserelin:
hot flushes (n = 1).
In patients who received chemotherapy 20/30 (67%)
patients had side effects. Five patients had both nausea
(WHO Grade I) and vomiting and a further four patients
had nausea alone, one of which was WHO Grade II. Four-
teen patients complained of lethargy, but only five were
judged to have WHO GII lethargy. Stomatitis occurred in
seven patients, but was WHO GII in only five patients, the
remainder being WHO GI. One patient lost her taste and one
developed sore eyes. Haematological toxicity was seen in five
patients, with the white blood cell count falling to
2.5-3.5 x 109 1' in all five, and one patients's platelet count
fell to 30 x 109 1'. All these five patients required between
20-30% dose reduction of chemotherapy, three after three
cycles and two after five cycles.
None of the patients, however, developed septicaemia or
bleeding episodes as a result of treatment.
We did not observe significant changes in the histological
appearance using collective histology of the first and second
biopsies obtained from the 23 patients who had surgery at 12
weeks.
The results at 65 weeks (Table IV) reveals that at com-
pletion of the chemotherapy (eight cycles) or endocrine
therapy (78 weeks - reviewed 65 weeks) there is no significant
difference in the number who are alive and well in each
group. Three patients have died, and three patients have
local recurrence in each group, seven have evidence of distant
metastases following endocrine therapy compared with only
four in the chemotherapy treatment patients. Salvage mastec-
tomy had been performed 32-60 weeks post-presentation in
four patients treated with chemotherapy and two patients
treated with endocrine therapy.
Table II Results of treatment (at 12 weeks)
Endocrine
therapy Chemotherapy
No. 30 30
Response
Complete response 0 8 A
= 0.001
Partial response 3 8
Minimal response 4 10
Stable disease 12 2
Progressive disease 11 2
Totals 30 30
Response *T4 Tumours regraded at 12 weeks
21 T4 6 3
T3 1 1
T2 3 4
TI 0 1
TO 0 2
*T3 Tumours regraded at 12 weeks
39 T4 3 1
T3 12 6
T2 5 4
TI 0 3
TO 0 5
30 30
*Here we have analysed the response of T3 and T4 tumours
separately and shown the results of the second assessment at 3
months.
Table III Definitive primary treatment (at 12 weeks)
Endocrine
therapy Chemotherapy
(a) Surgery T4 T3 T4 T3
Radical mastectomy 0 11 1 4
with radiotherapy 1 1 2 0
Wide local excision 0 1 0 0
with radiotherapy 0 2 0 0
(b) Radiotherapy
With endocrine treatment 6 4 0 0
With chemotherapy 1 0 7 15
(c) Chemotherapy*
Sole treatment 2 1 1 0
Total 10 20 11 19
*These patients had failed to respond to endocrine therapy and
two had developed metastatic disease. Chemotherapy was given as
palliative therapy.
Table IV Result of treatment (65 weeks)
Endocrine
therapy Chemotherapy
T4 T3 T4 T3
Dead 2 1 1 2
(1 LVF)
Alive, Distant metastasis 2 5 2 2
Alive, Local recurrence 3 0 1 2
Alive and well 3 14 7 13
Total 10 20 11 19
Survival curves were constructed for patients in each arm of the
Study using Cox regression. There was no difference in either
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Discussion
This is the first reported trial to compare endocrine therapy
and chemotherapy as primary treatment for locally advanced
breast cancer. The principal finding is that 26/30 (90%) of
patients randomised to receive combination chemotherapy
showed a greater than 25% reduction in tumour volume at
12 weeks, and in eight patients, the tumour became impal-
pable. This therapy is well tolerated and resulted in
significant myelosuppression in only five patients. Nausea
and vomiting was well controlled in all but a minority of
patients and alopecia was rarely seen. Twenty-nine of 30
patients completed their chemotherapy. As expected we
observed a disappointing response to endocrine therapy as
primary therapy, but the side effects were considered
minimal. We did not observe the 'flare' occasionally seen in
tamoxifen treated patients. The other advantage of 4-
hydroxyandrostenedione was that the parenteral route of
administration ensured that the patients actually received the
treatment. However, only 21 of 30 patients completed their
endocrine therapy due to change in treatment because of a
change in disease status.
A possible explanation for the response rate is the rate of
regression achieved by these different forms of treatment.
Thus, endocrine therapy caused a slower reduction in size
than chemotherapy, resulting in a response in 7/30 patients.
We would expect that certainly a proportion of these patients
would achieve partial and/or complete responses if treatment
were continued, as we have observed in elderly patients
(Gazet et ai., 1988). However, we felt that definitive local
treatment in these younger women could not be delayed
longer than 12 weeks, and this is reflected in the higher rate
of surgery in the endocrine arm of the study. However, at 65
weeks on completion of the trial, it is clear that there has
been no significant difference between chemotherapy or
endocrine therapy in relation to death, local recurrence, dis-
tant metastases and disease-free survival. Secondary surgery
is higher in the chemotherapy arm.
Since this study began, we now have clear evidence that
immunocytochemical prediction of response to endocrine
therapy is reliable (Coombes et al., 1971). Using Trucut
biopsy or fine needle aspiration material it is possible to
determine the ER status by immunocytochemistry (ERICA)
prior to treatment and this allows the preferred treatment,
endocrine for ER positive and chemotherapy for ER negative
patients, to be offered. In this study, we were able to measure
ER by immunotochemistry in 13 patients before treatment
and 12/13 showed >50% cells stained i.e. were ER positive
(Coombes et al., 1987). Amongst those 12 were the three
responders to endocrine therapy. We were able to obtain six
samples at 12 weeks for repeat ER and obtained similar
results as the pretreatment estimation (both samples positive
in five instances and both negative in a single case).
This pilot study has significant limitations in that the small
number of patients studied means that we can only analyse
response rates in the short term. Future trials will establish
the impact of this form of primary systemic treatment on
mortality from this disease. However, we feel that improved
survival may result since it will be possible to select adjuvant
therapy more accurately (a) selecting those that are endocrine
sensitive using immunocytochemical tests, (b) by evaluating
sensitivity of the primary tumour and thus response of
micrometastases (McClelland et al., 1986; Coombes et al.,
1986; Mansi et al., 1987).
Our finding has two important clinical implications.
Firstly, a significantly greater proportion of patients had
conservative surgery or did not require surgery initially
because of complete disappearance of the tumour in the
chemotherapy arm of the study. Secondly, the degree of
reduction in size achieved by primary chemotherapy may well
reflect the sensitivity of micrometastases to systemic
chemotherapy and this could be a highly significant prognos-
tic feature in patients with breast cancer.
Further studies are now needed to define the role of
immunocytochemistry in defining more accurately responders
to endocrine therapy. More recently newer techniques which
may provide additional information to ER have been
adovated including (a) the presence of progesterone receptors
that can now be measured immunocytochemically (Perrot-
Applanat et al., 1987; Berger et al., 1989); (b) the presence of
the oestrogen-induced protein PS2 that is related to outcome
(Rio et al., 1988; Skilton et al., 1989) and (c) the absence of
EGFR which can also be detected immunocytochemically
(Sainsbury et al., 1987).
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